Changes
/* Global Acne Medications Market */
[[Image:BCC ACNE.jpg|center|]]thumb|center|632px * 341px|Source: BCC Research,[http://www.marketresearch.com/BCC-Research-v374/Skin-Disease-Treatment-Technologies-Global-7616658/ BCC Research]]]
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|align = "center"|<font color="#282828"><font size = "4">'''The Acne Product Pipeline'''</font></font>
[[Image:USACNE2012.jpg]] |center|thumb|center|632px * 341px|Source: IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html IBIS World]]]
===Industry Forecast===
* Improving economic conditions is likely to drive the market, as greater disposable income growth allows consumers to spend on higher-priced over-the-counter (OTC) items.
[[Image:US2018 acne.jpg|center|thumb|center|632px * 341px|Source: IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html IBIS World]]]
===Major Players in Acne Space===
* J&J (Neutrogena, Clean & Clear, Aveeno, Ambi) commanded over 28.8% of anti-acne preparation sales in 2012. J&J’s closest rival was Guthy Renker,(Proactiv Solutions) which had a 24.6% share followed by Reckitt Benckiser at 14.7%.
[[Image:US Acne Share.jpg|US Acne Share.jpg]]|thumb|center|632px * 341px|Source: IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html IBIS World]]]
===Consumer Target Group & Product Categorization===
